Curis (CRIS) AI Stock Analysis

• Market Cap: $18.31M
• Dividend Yield: N/A
• Average Volume (3M): 107.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.83
• Revenue Growth: 14.17%
• EPS Growth: 28.26%
• Country: US
• Employees: 34
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): 1.25
• Shares Outstanding: 10,462,250
• 10 Day Avg. Volume: 175,426
• 30 Day Avg. Volume: 107,859
• PEG Ratio: -0.05
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.94
• Enterprise Value/Market Cap: 2.10
• Enterprise Value/Revenue: 0.90
• Enterprise Value/Gross Profit: 3.46
• Enterprise Value/Ebitda: -0.21
• 1Y Price Target: $14.50
• Price Target Upside: 728.57% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 39 Underperform
• Price Target: $1.50 ▼(-14.29%Downside)

Curis' overall stock score is primarily impacted by its financial instability, with persistent losses and negative cash flows posing significant risks. The bearish technical indicators further weigh on the score. While clinical trial progress offers potential, the immediate financial challenges overshadow these developments.

Positive Factors

Drug Development

Emavusertib is the only IRAK4 inhibitor in late-stage clinical development, positioning it uniquely in a crowded market.

Regulatory Support

Curis has received a positive regulatory foundation from both FDA and EMA, enhancing its potential market success.

Negative Factors

Enrollment Challenges

The primary challenge is the difficulty of enrollment, given the small patient population.

Stock Valuation

The price target is being lowered due to dilution from a recent raise, which could impact the stock's valuation.

Curis Business Overview & Revenue Model

Company Description

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

How the Company Makes Money

Curis primarily makes money through the development and commercialization of cancer treatments, with revenue generated from product sales, licensing agreements, and strategic partnerships. The company enters into collaboration agreements with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties based on the successful development and commercialization of their drug candidates. Additionally, Curis may receive research funding from partners to support its ongoing research and development efforts.

Curis Financial Statement Overview

Summary

Curis faces significant financial challenges with persistent losses and negative cash flows. Revenue growth is evident, but the company struggles with profitability and a fragile balance sheet, indicated by negative equity and ongoing operational losses.

Income Statement

Curis shows a slight increase in revenue from the previous year, but the company still suffers from significant negative net income and EBIT margins, indicating ongoing profitability issues. The gross profit margin remains positive, but the net profit margin is deeply negative, reflecting operational challenges.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, which is concerning, indicating that liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity. This highlights potential solvency issues and financial instability.

Cash Flow

Curis has negative free cash flow and operating cash flow, which are troubling. The cash flow from operations is consistently negative, which may indicate difficulties in generating cash from core activities. Despite some improvement in cash flow from investing activities, the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.20M	10.91M	10.02M	10.16M	10.65M	10.84M
Gross Profit	11.12M	10.81M	9.81M	9.90M	10.12M	10.30M
EBITDA	-41.87M	-42.57M	-45.14M	-50.51M	-39.98M	-24.67M
Net Income	-42.13M	-43.39M	-47.41M	-60.32M	-50.64M	-34.88M
Balance Sheet
Total Assets	39.33M	41.27M	77.28M	108.85M	162.30M	204.36M
Cash, Cash Equivalents and Short-Term Investments	20.28M	20.00M	56.33M	85.62M	139.85M	183.06M
Total Debt	2.64M	2.95M	2.79M	6.74M	5.04M	7.66M
Total Liabilities	45.93M	47.26M	57.61M	62.30M	71.59M	73.69M
Stockholders Equity	-6.61M	-6.00M	19.67M	46.55M	90.71M	130.67M
Cash Flow
Free Cash Flow	-33.58M	-39.56M	-38.43M	-54.75M	-37.62M	-26.42M
Operating Cash Flow	-33.58M	-39.56M	-38.43M	-54.34M	-37.62M	-25.74M
Investing Cash Flow	10.53M	29.44M	37.79M	33.02M	-47.90M	-49.05M
Financing Cash Flow	13.38M	3.44M	7.58M	867.00K	-4.17M	188.81M

Curis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Negative. The current price of 1.75 is below the 20-day moving average (MA) of 2.33, below the 50-day MA of 2.16, and below the 200-day MA of 3.27, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 34.37 is Neutral, neither overbought nor oversold. The STOCH value of 28.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRIS.

Curis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VVOS	53 Neutral	$22.56M	―	-450.47%	―	9.47%	81.37%
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%
LSTA	43 Neutral	$24.59M	―	-56.49%	―	―	7.07%
CRIS	39 Underperform	$18.31M	―	-2951.24%	―	14.17%	28.26%
BCAB	35 Underperform	$23.23M	―	-246.21%	―	―	44.38%
UBX	31 Underperform	$5.13M	―	-231.27%	―	―	35.08%
CVM	27 Underperform	$12.94M	―	-238.64%	―	―	30.96%

Curis Corporate Events

Curis Announces $7M Securities Purchase Agreement

On July 2, 2025, Curis, Inc. announced a securities purchase agreement with institutional investors to raise approximately $7 million through a combination of registered direct offerings and private placements. This financial move is expected to support the company’s operations into the first quarter of 2026, providing a cash runway to advance its research and development programs. The agreement includes the issuance of common stock and warrants, with the offerings anticipated to close by July 3, 2025, subject to customary conditions. The company has engaged Laidlaw & Company and JonesTrading Institutional Services as co-placement agents for the transaction.

The most recent analyst rating on (CRIS) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.

Curis Approves Key Amendments at Annual Meeting

On May 20, 2025, Curis, Inc. held its Annual Meeting of Stockholders virtually, where several key amendments were approved. The stockholders approved an amendment to the company’s stock incentive plan to reserve an additional 1,255,000 shares of common stock, increasing the total authorized shares for issuance. Additionally, an amendment to the company’s Restated Certificate of Incorporation was adopted, increasing the number of authorized shares of capital stock and common stock significantly. The board also approved changes to the company’s bylaws, reducing the quorum requirement for stockholder meetings. These changes aim to enhance the company’s operational flexibility and shareholder engagement.

The most recent analyst rating on (CRIS) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.